Ypsomed announced today that it concluded a long-term supply agreement with Novo Nordisk for large quantities of autoinjectors.
Burgdorf, Switzerland-based Ypsomed designed the autoinjectors to administer drugs for the self-treatment of metabolic conditions. It intends to deliver variants of its YpsoMate 1mL autoinjector for various drugs undergoing clinical trials in large quantities. This expands its manufacturing capacities over the coming years.
Novo Nordisk expects to contribute a significant part of the investment for additional production infrastructure. The companies expect availability of a significant capacity of autoinjectors for Novo Nordisk “in the course of 2025.”
Get the full story at our sister site, Drug Delivery Business News.